Folia Biologica
Journal of Cellular and Molecular Biology, Charles University 

Crossref logo

Fol. Biol. 2002, 48, 242-245

https://doi.org/10.14712/fb2002048060242

Freezing and Thawing of Murine Bone Marrow-Derived Dendritic Cells Does Not Alter Their Immunophenotype and Antigen Presentation Characteristics

Luis Mendoza1, J. Bubeník1, M. Indrová1, J. Bieblová1, V. Vonka2, J. Šímová1

1Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
2Institute of Haematology and Blood Transfusion, Prague, Czech Republic

Received October 2002
Accepted October 2002

The aim of this paper was to assess whether the BMDC after freezing and thawing are capable to retain the immunophenotype and antigen-presenting capacity. BMDC were generated from bone marrow precursor cells as described previously by culturing the cells in medium containing GM-CSF and IL-4. Afterwards, the cells were harvested, counted and used for phenotyping and priming of syngeneic spleen cells. For cryopreservation, the BMDC were frozen in the presence of 10% of dimethylsulphoxide (DMSO) and 90% foetal calf serum. Forty to fifty percent of both samples, frozen/thawed as well as fresh BMDC, exhibited characteristic DC morphology, and the DC obtained from the frozen/thawed samples expressed a similar level of MHC class I-, MHC class II-, CD80-, CD86-, CD11c-, CD11b-, CD54- and CD205-molecule as fresh DC. To examine the in vitro priming effect of cryopreserved BMDC on syngeneic non-adherent murine C57BL/6 (B6) spleen cells, the BMDC were thawed, pulsed with the lysate prepared from HPV 16-associated tumour MK16 and used for 3H-thymidine assay. The findings of the experiments indicate that fresh as well as cryopreserved murine BMDC preparations pulsed with tumour lysate were efficient to prime the mitogenic activity of syngeneic non-adherent splenocytes. Taken together, the results suggest that frozen/thawed BMDC are morphologically, phenotypically and functionally comparable with fresh BMDC and can be used for construction of dendritic cell-based tumour vaccines.

Funding

This work was supported by grants No. NC/7148 from the Grant Agency of the Ministry of Health of the Czech Republic; Nos. 301/00/0114, 301/01/0985 from the Grant Agency of the Czech Republic; Nos. A7052002, IAA5052203 from the Grant Agency of the Academy of Sciences of the Czech Republic; and by the League Against Cancer, Prague.

References

9 live references